Modality
Bispecific Ab
MOA
ALKi
Target
WRN
Pathway
DDR
GBMUrothelial Ca
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
Apr 2019
→ Sep 2030
Phase 1Current
NCT07117997
1,886 pts·GBM
2021-03→2030-09·Completed
NCT03273792
172 pts·Urothelial Ca
2019-04→2029-11·Terminated
2,058 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-11-213.6y awayInterim· Urothelial Ca
2030-09-024.4y awayInterim· GBM
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Termina…
P1
Complet…
Catalysts
Interim
2029-11-21 · 3.6y away
Urothelial Ca
Interim
2030-09-02 · 4.4y away
GBM
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07117997 | Phase 1 | GBM | Completed | 1886 | NT-proBNP |
| NCT03273792 | Phase 1 | Urothelial Ca | Terminated | 172 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 |